Search

Your search keyword '"Arana-Yi, Cecilia"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Arana-Yi, Cecilia" Remove constraint Author: "Arana-Yi, Cecilia"
172 results on '"Arana-Yi, Cecilia"'

Search Results

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

4. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

7. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

8. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

9. Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants

10. P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

11. P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL

12. P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

13. P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

14. P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.

15. Avapritinib versus Placebo in Indolent Systemic Mastocytosis

16. Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

17. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

19. MPN-332 Initial Results From Summit: An Ongoing, 3-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients With Non-Advanced Systemic Mastocytosis (NonAdvSM)

20. Initial Results From Summit: An Ongoing, 3-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients With Non-Advanced Systemic Mastocytosis (NonAdvSM)

22. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

23. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

24. Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.

25. Characteristics and prognosis of mutated STAG2 myeloid neoplasms.

26. Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts

27. Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

31. Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort

34. Single-Hit TP53mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

37. Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

41. Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

42. Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes

46. A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).

47. Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.

48. Compromiso intestinal en la enfermedad de Buerger (Tromboangeitis Obliterante): Reporte de un caso

49. Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Catalog

Books, media, physical & digital resources